NEWSLETTER 27 January 2018
|
|
- Jeffery Hill
- 6 years ago
- Views:
Transcription
1 NEWSLETTER 27 January 2018
2 I am calling this our inaugural newsletter, but it is not so much a newsletter as a welcome on board and a brief introduction to the company you now part-own. Nyrada has been underway effectively for the past 3 months as control and operation of its 3 drug assets transitioned from Noxopharm and Altnia. Being in transition still meant that the R&D programs continued, but at something short of full pace with limited personnel and funding. With the transitioning now complete and subscription funds about to be released, Nyrada is able to start the process of getting into full swing. Company Snapshot We are a drug discovery and drug development company. There is no notion at this stage of doing anything more than bringing new drugs into the clinic, establishing their therapeutic potential, and then finding someone else to take the drug through the final steps of the regulatory process and bringing it to market. The 80:20 rule classically applies to drug development: getting an experimental drug to the point of being 80% confident of its final success represents about 20% of that drug s final cost of development. Nyrada does not need to be taking on the final 80% of the cost of that exercise, even if that process represents just 20% of the total development time. Passing a drug onto someone else might vary between a trade sale of a particular asset, or a license, or a partnership, or something else more creative. Irrespective of the nature of the deal, at this stage our horizon is Phase 2 clinical stage development. We also will be focusing on drug development in areas of high community demand. And with high community need comes high pharmaceutical industry interest. The 4 therapeutic indications we currently are exploring, happen to be areas of considerable interest for big pharmaceutical companies. Large acquisitions are taking place, and we will be looking to position individual Nyrada assets to that end. We are a US company. It s not difficult to guess why.. the US capital markets are where we expect to get greater attention and better value for the stock. It is the home of wealthy foundations and significant government funding, with our 3 therapeutic indications the targets of substantial funding activity. The strategy is to conduct our business largely in Australia for the next 2 years, with a growing foothold in the US, eventually leading to the Company s HQ being relocated to the US in early In the Company s 2 formative years, it makes sense to not have to duplicate the administrative, pre-clinical and clinical resources within Noxopharm.
3 We aim to list. The aim is to provide liquidity for our shareholders, as well as having ready access to capital markets for fund-raising. The timing is as soon as possible, but obviously will be dependent on a number of factors, some of which are under our control, and others that are not. The current plan is to seek a listing on the ASX under the CHESS Depositary Interest (CDI) facility. This is a process requiring the issue of a full prospectus and having a minimum of 300 shareholders. A NASDAQ listing is an obvious objective as well, but our current strategy is to pursue an ASX listing first. We intend to be focused. Given the high-risk, binary nature of drug development, diversity is a sensible de-risking strategy in this high-stakes game. But diversity also carries the risk of distracting people and of diluting effort and scarce resources. That is why Noxopharm carved out Nyrada in the first place. Nyrada is deliberately de-risked. It starts life pursuing 3 broad therapeutic indications: 2 of them are neurological in nature, and 1 non-neurological. Each one of these programs is too early in development to be playing favourites because at this early stage each one has got roughly equal proof-of-concept and equal likelihood of making it to market. So, each is being given equal resources. But, right now, the starting intention is to focus eventually on neurological drug development, and to add as much value as we can to our non-neurological asset over the next 2 years before looking to pass it on to pharma companies that specialises in the field of cardiovascular health. The one predictable aspect of drug development is its unpredictability, and we intend that Nyrada will be sufficiently advised and smart enough to recognise opportunity and to make the right calls on its scientific and commercial strategies. A neurosciences company. That is how we envisage Nyrada. Of course, that vision will always be open to change as we stay alert to opportunity and circumstances, but it is our starting vision. Neurodegenerative disease is one of medicine s great unexplored frontiers with an enormous call for medicines across a wide spectrum of diseases and conditions. But this is a call that remains largely unanswered. For example, no drug is approved for the treatment of loss of hearing, or for the underlying disease processes in Alzheimer s, or Huntingdon s, or Parkinson s, or ALS (motor neurone disease), or multiple sclerosis, or direct injuries to the nervous system such as stroke, trauma and drug side-effects. Under any other circumstances, such need would have been met with a wave of companies entering the field. But the human nervous system presents a raft of challenges not found in other systems, most of which have presented insurmountable barriers up to now. Those barriers have led to significant constraints on companies in the neurosciences field, typically restricting them to focus on treating the symptoms of disease, rather than addressing the underlying disease processes and seeking to stop their progression.
4 Nyrada has a vision of being able to block the progressive nature of many common neurodegenerative diseases and disorders, rather than just their symptoms. That vision has its basis in two proprietary drug technologies that address two key underlying pathologies common to most neurodegenerative diseases: excitotoxicity and inflammation. NYX-104 is our lead drug in the field of excitotoxicity, and NYX-205 in the field of neuroinflammation. Management Board of Directors Scientific Advisory Panel Chair: Prof. Gary Housley Dr Graham Kelly CEO James Bonner V-P. R&D Mark Waring Senior V-P. US Operations R&D team Board The Board currently stands at 3: Dr Graham Kelly (Executive Chairman and CEO), Mr Peter Marks (Non-Executive Director) and Mr Josiah Austin (Non-Executive Director). Josiah is a US citizen and resident and is an Independent Director. Another 2 directors are to be appointed.
5 Scientific Advisory Board The Scientific Advisory Board will provide general guidance to the Board of Directors on scientific and commercial strategies, and to advise the executive and scientific teams on the conduct of the various R&D programs. The Advisory Board is chaired by Scientia Professor Gary Housley, who holds the UNSW Sydney Chair of Physiology, and is Director of the Translational Neurosciences Facility at UNSW. Professor Housley is to be joined by 4 other eminent scientists, 2 others in the field of neuroscience and 2 in the field of blood lipid metabolism. These scientists have been identified and approached, and currently are in the process of having their appointments confirmed. CEO The appointment of Graham Kelly as CEO is an interim step only and is a part-time position. The intention is for Graham to see the Company through its formative stages and to have identified and appointed a full-time CEO by the time the Company is ready to relocate its headquarters to the US. Graham s appointment is expected to be for no more than 24 months. Executive James Bonnar has joined the Company as Vice-President, Research & Development. James has had a distinguished career in neurological drug development in the biotechnology sector. In addition to overseeing all R&D in Nyrada, James will take personal control of the NYX-104 (neuroprotectant) drug program, an area in which he has considerable experience. Mr Mark Waring is Senior Vice-President, US Operations. Mark is based in the US and will anchor the Company s activities there for the next 2 years ahead of the Company s relocation to New York. R&D Team Dr Benny Evison is Director, Anti-Inflammatory Drug Program. Benny has been with Nyrada for 9 months and is responsible for bringing all 3 drug programs to their current position. In the short-term, Benny will focus on the NYX-205 drug program. A Director, Cardiovascular Drug Program currently is being sought. An additional 2 scientists are to be appointed by March to complete the R&D team at this stage. Further appointments will be made as the R&D programs expand. Ancillary resources For the foreseeable future, most other corporate and research resources will be supplied by Noxopharm under a general services agreement. Over time as the need arises, Nyrada will switch to in-house resources. General office management, HR, chemistry, drug manufacture, regulatory affairs and clinical trial management, all will be provided by Noxopharm on a contractual basis.
6 The science Now to the business end of the Company. Three drugs and multiple indications. It s a full book of work. And it s important and potentially ground-breaking work. NYX-104 Excitotoxicity. The extraordinary self-destruct phenomenon, seemingly peculiar to the nervous system, that continues to damage and kill nerve cells, for days and weeks following an acute injury. A phenomenon that means greater damage, and therefore delayed recovery, after physical injury to the central nervous system (brain and spinal cord) from events such as stroke, concussion, severe epileptic seizure, physical trauma and loud noise. A phenomenon that manifests in permanent disability after stroke, or early onset dementia in professional sportspeople, or hearing impairment in service men and women. A common phenomenon in our community in urgent need of an effective therapy. Our aim is to develop NYX-104 as a first-in-class neuroprotectant to meet this need. Where we are up to R We have achieved the key first step in any drug development program in having identified a potential drug candidate. Professor Gary Housley s team at UNSW have made significant progress recently in groundbreaking research that has led to a better understanding of the biochemical processes underlying excitotoxicity. A key protein and signalling pathway have been identified and a patent lodged by UNSW, with the first grant of this patent recently achieved. NYX-104 is a small molecule drug selected initially for its ability in the laboratory to block the excitotoxicity pathway described by Professor Housley s team. When given to mice bearing a brain injury mimicing human stroke, NYX-104 blocked the extent of post-injury brain death (excitotoxicity) by 60%. This is key proof-of-principle data that gives the Company confidence that it has a potential major new therapeutic on its hands.
7 Using the Noxopharm LIPROSE drug delivery system, NYX-104 was delivered rectally to the mice, leading to the formation of a pro-drug form of NYX-104 that crosses the blood-brain barrier of the mice, reaching brain tissue in relatively high, therapeutic levels. For the scientifically-minded, NYX-104 is a kinase inhibitor, which is a drug that inhibits the ability of kinases, enzymes that activate (phosphorylate) proteins. In the case of NYX-104, we believe it is inhibiting the proteins identified by Professor Housley that are involved in the mobilisation of calcium in neurons. It is this mobilisation of calcium in response to injury that is a major factor in the cascade of neuronal cell death that occurs with strokes and brain injuries. What we need to do now Before we can even think about starting human studies, we need to do the following basic studies: a) We believe that NYX-104 is our final molecule. But we need to be certain. This means testing in the laboratory more compounds closely related to NYX-104 to see if we can find a more powerful compound. b) Develop both intravenous and suppository dosage forms of NYX-104 for acute and chronic administration respectively. c) Test the final drug in a large animal model of brain injury. d) Determine the extent of off-target activity of the drug and its safety in animals. Steps (b), (c) and (d) are proceeding with NYX-104 on the basis that a more powerful molecule is unlikely to be found. Step (a) is current; should a better (or equally potent) lead molecule emerge, then it will be developed in parallel with NYX-104 to provide a competitive selection process. The intellectual property pertaining to the chemical composition of the NYX-104 family of compounds and target action are part of the Nyrada patent portfolio. This is not going to be a quick route into the clinic. The Company is facing several years of study to prove that the drug is sufficiently likely to provide a therapeutic benefit in humans and likely to be without significant safety issues. But each step we take brings us closer to the clinic and increases the value of this asset. And we won t be on this journey alone. We are going to seek collaborations with highprofile clinical research groups around the world in order to expedite entry into the clinic across a number of different clinical indications. NYX-205 NYX-205 is an anti-inflammatory drug. More specifically a drug that inhibits the formation of one of the key contributors to inflammation. a hormone known as thromboxane.
8 After decades of flying under the scientific radar, thromboxane has emerged in recent years as a putative key player in the inflammatory processes associated with many neurodegenerative diseases. The challenge with this discovery is that there are remarkably few drugs that specifically inhibit the production of thromboxane, coupled with a complete absence of any such drugs able to cross the blood-brain barrier to inhibit thromboxane production in the brain. Our aim is to develop NYX-205 as the first specific inhibitor of thromboxane production, with the additional key feature of being able to cross the blood-brain and blood-nerve barriers to treat inflammation of the central nervous system (brain and spinal cord) and peripheral nerves. Neuro-Inflammation. Inflammation is the body s response to injury, designed to kick-start the repair process. Once the injury subsides and the repair process is complete, the inflammatory process then retreats and the tissue returns to normal function. But where the underlying injury or disease process persists, then the inflammation also persists and eventually becomes chronic. Chronic inflammation then becomes a disease in itself on top of the original injury or disease, typically causing loss of function in its own right. Inflammation of nervous tissue (neuro-inflammation) follows anything that injures nerve cells. This can be as varied as physical trauma, deprivation of oxygen, chemical poisons, genetic malfunction and viruses. And while inflammation in any tissue is a complex interplay between numerous hormones and chemicals, thromboxane has emerged in recent years as a likely key player in neuro-inflammation, marking it, therefore, as a key drug target. NYX-205 blocks the production of thromboxane by inhibiting the function of the enzyme responsible for its manufacture, thromboxane synthase. NYX-205 specifically inhibits thromboxane synthase without affecting the production of the other key component of inflammation, the prostacyclins, which are the target of the great majority of antiinflammatory drugs used in humans. Thromboxane was long thought to be a relatively minor player in the inflammatory process being produced by blood platelets, with major functions being to clump platelets and to cause blood vessels to contract. We now know that it is produced by a wide variety of tissues and to play broad and integral roles in inflammatory and immune responses to tissue injury. Recent experiments in a mouse model of Alzheimer s Disease found that blocking thromboxane activity in the brain put a very considerable brake on the development of structural changes in the mouse s brain associated with dementia. Where we are up to R NYX-205 is confirmed as a potent inhibitor of thromboxane synthase. It is our confirmed lead candidate drug, meaning we are able to proceed with the standard preclinical development process leading up to human studies.
9 What we are doing now While neuro-inflammation in diseases such as Alzheimer s, Parkinson s, Huntingdon s and amyotrophic lateral sclerosis (ALS, or motor neurone disease) are the obvious long-term therapeutic targets for NYX-205, clinical trials in those indications will be challenging. The Company has adopted a strategy of first proving the clinical benefit of NYX-205 in more readily accessible clinical models, which in their own right still represent major commercial opportunities. The clinical target we are pursuing is peripheral neuropathy, or loss of function of the nerves supplying the hands and feet. The loss of function follows loss of their myelin (insulating) sheath as a result of chronic inflammation. It is a common side-effect of certain common cancer chemotherapies in both adults and children, as well as a common outcome in patients with Type 1 diabetes. The barrier that prevents most drugs from reaching the brain, is the same barrier that prevents drugs being able to reach peripheral nerves (the so-called blood-nerve barrier). Providing evidence of clinical benefit in peripheral neuropathy, while of significant community benefit in its own right, should provide the rationale for extending studies of NYX- 205 use into central nervous system indications. Nyrada currently is conducting studies in collaboration with a research group at UNSW (Sydney) using a mouse model of cisplatin-induced peripheral neuropathy. Those studies are intended to provide the necessary proof-of-principle evidence of NYX-205 therapeutic benefit required to justify clinical studies in cancer patients experiencing side-effects of peripheral neuropathy. NYX-330 This is the Company s single non-neurological drug program. NYX-330 is under development as a treatment for hypercholesterolemia, or elevated blood levels of LDL (low density lipoprotein) cholesterol where it presents a risk factor for cardiovascular disease. After almost 3 decades of relying on the so-called statin drugs to lower LDL levels, the therapeutic target has shifted from blocking the production of LDL cholesterol, to increasing the rate at which LDL cholesterol is removed from the body. Driving this shift is the roughly one-third of patients dosed with statin drugs who need to stop treatment because of unwanted side-effects and the roughly one-third in whom the treatment fails to deliver the targeted clinical effect. The new target is the protein, PCSK9, a plasma protein that regulates the clearance of LDL cholesterol from the bloodstream. The more PCSK9 protein that a person has in their
10 bloodstream, the less able that person is to clear the LDL cholesterol from the blood and the higher LDL cholesterol levels rise. The following diagram shows the dynamics of removal of LDL cholesterol from the blood. The surface of liver cells (hepatocytes) express a protein (LDL-receptor, or LDLR) that attaches to the LDL cholesterol particles as the blood passes through the liver. This forms a 2-party complex (cholesterol particle + LDLR) that moves inside the liver cell where the LDL cholesterol particle s broken down. The LDLR then recycles to the surface of the liver cell to repeat the action. If PCSK9 is present, it interferes in this dynamic by binding to the LDLR-cholesterol complex, forming a 3-party complex that once inside the liver cell, leads to the complete degradation of all 3 components, including the LDLR. Without the ability to recycle the LDLRs, the outcome is a net loss of LDLRs and a resulting decreased capacity of the liver to remove LDL cholesterol from the blood. NYX-330 is a small molecule that has been designed to block the ability of the plasma protein, PCSK9, to bind to the LDL receptor-ldl cholesterol particle complex. NYX-330 is being developed as an oral, well-tolerated medication that either will augment the efficacy of statins in those individuals unsatisfied with the statin benefit, or to replace statins in patients unable to tolerate statins. Where we are up to R NYX-330 is confirmed in the laboratory as blocking binding between PCSK9 and LDLR, and in mice as having an appropriate pharmacokinetic profile in terms of blood levels and drug half-life and being well tolerated after short-term dosing.
11 What we are doing now a) We believe that NYX-330 is our final molecule. But as with NYX-104, we need to be certain. This means testing in the laboratory chemical variations of NYX-330 to see if we can find a more powerful compound. b) Develop an oral dosage form that optimises the bio-availability (rate of absorption) of NYX-330. c) Determine the extent of off-target (potentially unwanted activity) by both laboratory tests and animal safety studies. Investor relations The Nyrada shareholder base currently stands at just under 30 entities. Being an unlisted company carries certain advantages in terms of communication, although we still are a public company and a subsidiary of Noxopharm, a listed company, and that brings certain restrictions and obligations. I intend to keep you regularly updated on progress with both our R&D and corporate activities. Where we see any news as market sensitive, then we likely will release it as a Noxopharm ASX announcement. My address is graham.kelly@nyrada.com. My telephone contact is Don t hesitate to contact me with any questions. GRAHAM KELLY Executive Chairman and CEO *Declaration: Professor Housley is a shareholder of Nyrada.
Antisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More informationDeveloping innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
More informationKRISANI BIO SCIENCES PVT. LTD.
KRISANI BIO SCIENCES PVT. LTD. Flat B2, 2 nd Floor, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad, Telangana 500078. Email: kkr@krisanibio.com. URL: www.krisanibio.com Contact Number: +91 98494
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT
FOR IMMEDIATE RELEASE December 21, 2017 Eisai Co., Ltd. Biogen Inc. ADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT CRITERIA FOR SUCCESS AT 12-MONTH ANALYSIS
More informationSwissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia
Published: 07:00 04.10.2007 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Liestal and
More informationPascal Quiry March 2013
Please send any questions on this case study to the author via the mail box on the web site www.vernimmen.com Pascal Quiry March 2013 This document may not be used, reproduced or sold without the authorisation
More informationSTEM CELLS IN NEUROLOGY ISABELLE COCHRANE MERIT
STEM CELLS IN NEUROLOGY BY ISABELLE COCHRANE MERIT RESEARCH PAPER BASED ON PATHOLOGY LECTURES AT MEDLINK 2011 1 Abstract Ever since their discovery, stem cells have been heralded as the ultimate cure to
More informationEARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles
EARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles BrainDTech team Dr. Fabio Bianco, PhD Chief Executive Officier PhD in Pharmacology, Degree in Biotech
More informationINVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE!
INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE! TOPADUR PHARMA AG a promising Swiss start-up investment Global Medical Need: Diabetes mellitus is one of the major health concerns worldwide.
More informationINUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR REGENERATIVE MEDICINE
INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR > SOLUTIONS AND HOPE Millions of people worldwide suffer from deadly diseases, chronic conditions and congenital disorders
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationINITIATOR PHARMA: Q3 REPORT 2017
INITIATOR PHARMA: Q3 REPORT 2017 Initiator Pharma A/S, a Danish Biotech Company developing a novel treatment of Erectile Dysfunction. Financial Highlights Initiator Pharma A/S is a Danish registered company,
More informationStem cells and motor neurone disease
Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and includes details of the current
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationAxel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK
Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationFor personal use only
Antisense Therapeutics Ltd AGM Presentation and Questions on notice November, 2016 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and
More informationTheranexus files its registration document as part of its planned Initial Public Offering (IPO) on the Euronext Growth market in Paris
This press release cannot be published, transmitted or distributed, directly or indirectly, in the United States, South Africa, Canada, Australia or Japan. This press release does not constitute an offer
More informationApplication of Deep Learning to Drug Discovery
Application of Deep Learning to Drug Discovery Hase T, Tsuji S, Shimokawa K, Tanaka H Tohoku Medical Megabank Organization, Tohoku University Current Situation of Drug Discovery Rapid increase of R&D expenditure
More informationAD/PD Conference, Nice, Fr, 2015
AD/PD Conference, Nice, Fr, 2015 Overview, novelties and conclusions for domestic research NAP B MTA TTK MS Neuroproteomics Group Overlaping molecular mechanisms of miss-folded protein based neurodegenerative
More information105 AUSGABE 07 MAI 2014
105 AUSGABE 07 MAI 2014 DER NEUE FORSCHUNGSDRANG Dieser Mann hat Multiple Sklerose und sucht selbst nach einem Heilmittel. Wie der US-Amerikaner Scott Johnson zusammen mit der Hertie-Stiftung die Medikamentenforschung
More informationBuilding a Career in the Pharmaceutical Industry: Personal Reflections. Carlo Nalin, PhD Executive Director Novartis Oncology
Building a Career in the Pharmaceutical Industry: Personal Reflections Carlo Nalin, PhD Executive Director Novartis Oncology 2 Career Development: Personal Reflections C Nalin 5 April 2016 Cornell BEST
More informationuniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value
uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Company Structure Simplified; Manufacturing to be Consolidated into Lexington,
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationAmsterdam, the Netherlands 29 March 2018
Esperite (ESP), The Cell Factory presents preclinical results on the new products of the 2 nd generation EV s drugs for treatment of inflammatory diseases Esperite with its biotech company The Cell Factory
More informationDr Amy Prosser Careers in Research: Industry
www.rsb.org.uk Dr Amy Prosser Careers in Research: Industry @RoyalSocBio #BiologyWeek #RSBcareersDay Careers in Research: Working in the Pharma Industry Dr Amy Prosser My Career History 2011 Completed
More informationBreaking boundaries in MS research. Sorrel Bickley Research Communications Manager
Breaking boundaries in MS research Sorrel Bickley Research Communications Manager Disclaimer Research Team are not medical professionals If anyone is worried about the treatments they are taking speak
More informationGENOMICS: THE KEY TO TOMORROW S TREATMENTS? Jim Sullivan, PH.D. Vice President, Discovery AbbVie
GENOMICS: THE KEY TO TOMORROW S TREATMENTS? Jim Sullivan, PH.D. Vice President, Discovery AbbVie Ideas that Change Healthcare, Kings Fund, 06/10/17 AXGOV171426 Date ofpreparation: October 2017 Genomics
More informationFactor X. Factor IIa (thrombin)
Protease Inhibitors: Innovation Drives Drug Pipeline Figure 1.2. Schematic of the Coagulation Cascade Tissue damage or inflammation Initiation Factor VIIa / Tissue Factor (TF) Factor IX Factor X Factor
More informationVoyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More informationhttps://us12.admin.mailchimp.com/campaigns/preview-content-html?id=500409
Page 1 of 5 Message from the Director: Over the past two weeks, we have seen a lot of activity among the PIIN membership. I would like to thank everyone who was involved with our Traumatic Brain Injury
More informationList of E-journals Subscribed for the year 2016 (January to December) Pharmacy Faculty Sl. No.
Faculty 1 Adolescent Psychiatry Psychiatry 2 Anti Cancer Agents in Medicinal / Pharma & Quality 3 Anti-Infective Agents Pharmaceutical Microbiology 4 Anti-Inflammatory & Anti- Allergy Agents in Medicinal
More informationQuarterly Report for the Period Ended 31 March 2018
Quarterly Report for the Period Ended 31 March 2018 Highlights Cash receipts of $617,440 received during the March quarter. Main royalty contributors were the SK-II Power Booster (throughout Asia) and
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell
More informationFujifilm s Initiatives in Regenerative Medicine
Fujifilm s Initiatives in Regenerative Medicine Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation March 30, 2015 Priority Business: Healthcare Expand business with focus on six core business
More informationInaugural Fraunhofer Delaware Technology Summit
Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationEstia Health Limited ACN ( Company ) Approved by the Board on 17 November 2014
Board Charter Estia Health Limited ACN 160 986 201 ( Company ) Approved by the Board on 17 November 2014 Board Charter Contents 1 Purpose of this charter 1 2 Role and responsibilities of the Board 1 2.1
More informationPHARMACOLOGY. Dr Paul Spiers, Dept of Pharmacology & Therapeutics Tel ,
PHARMACOLOGY COURSE COORDINATOR: Dr Paul Spiers, Dept of Pharmacology & Therapeutics Tel 896 2146, spiersj@tcd.ie ECTS Value 10 Credits Contact Hours 46 hrs lectures 2 tutorials 3 hr 2 computer sessions
More informationHandy Gelbard, Director Professor of Neurology, Pediatrics, Microbiology & Immunology and Neuroscience
The Center for Neural Development and Disease (will be The Center for NeuroTherapeutics Discovery) Handy Gelbard, Director Professor of Neurology, Pediatrics, Microbiology & Immunology and Neuroscience
More informationTissue Engineering and the Brain. Susan Perry Bioengineering Program Lehigh University
Tissue Engineering and the Brain Susan Perry Bioengineering Program Lehigh University ...all the most acute, most powerful, and most deadly diseases, and those which are most difficult to be understood
More informationThe Hunt for New Medicines Uses of Information from the Human Genome: Therapeutic Drug Targets
Biological Sciences Initiative HHMI The Hunt for New Medicines Uses of Information from the Human Genome: Therapeutic Drug Targets Therapeutic drugs or medicines can prevent the development of disease,
More informationNEUROLOGY AND OPHTHALMOLOGY
NEUROLOGY AND OPHTHALMOLOGY OPPORTUNITIES AT INSERM BD & L: Anne Cochi anne.cochi@inserm-transfert.fr September 2017 1 WE PROPOSE A SELECTION OF PROJECTS AT DIFFERENT STAGES 4 Neurodegeneration patents
More informationAppointment of: Programme leaders for the UK Dementia Research Institute
Appointment of: Programme leaders for the UK Dementia Research Institute Contents 3 About the UK Dementia Research Institute 4 Strategic vision 6 About the centres 8 Programme leader profile - UK DRI Professor
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationFrom Stem Cell to Any Cell
sciencenewsforkids.org http://www.sciencenewsforkids.org/2005/10/from-stem-cell-to-any-cell-2/ From Stem Cell to Any Cell By Emily Sohn / October 11, 2005 For maybe a day, about 9 months before you were
More informationThe TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices
A leading Australian contract research organisation (CRO) providing integrated preclinical drug development services to the biotech and pharmaceutical industries The TetraQ Difference Located at The University
More informationSTATEMENT SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION AND RESEARCH U.S. FOOD AND DRUG ADMINISTRATION BEFORE THE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 STATEMENT OF SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION
More informationDisclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationCorporate Governance Statement September 2016
Level 9, Waterfront Place 1 Eagle St, Brisbane QLD 4000 GPO Box 1164, Brisbane QLD 4001 Telephone: 07 3108 3500 Fax: 07 3108 3501 Email: admin@lanewayresources.com.au www.lanewayresources.com.au Corporate
More informationDecision Process for Committing to a Therapeutic Development Approach: Target Validation Metrics and Biomarkers
Decision Process for Committing to a Therapeutic Development Approach: Target Validation Metrics and Biomarkers Kalpana Merchant, PhD Chief Scientific Officer, Tailored Therapeutics - Neuroscience Eli
More informationDrug Repurposing. John P. Overington Stratified
Drug Repurposing John P. Overington Stratified Medical @johnpoverington Stratified Medical Deep Learning in Drug Discovery ~1,500 drugs ~1,000,000,000,000,000,000,000 drug-like molecules Drug Disease ~5,000
More informationMOSAIQUES DIAGNOSTICS
MOSAIQUES DIAGNOSTICS CLINICAL PROTEOMICS IN DRUG DEVELOPMENT INFORMATION Clinical Proteomics for early and differential diagnosis FDA Letter of Support Possibilities of a companion test in Drug Development
More informationMyeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation
Myeloma Bone Disease Current and Future Treatment A Publication of The Bone and Cancer Foundation What Is Multiple Myeloma? Multiple Myeloma is a cancer that results from a malignant change in a particular
More informationFor personal use only
For personal use only A clinical-stage drug development business Investor Update Dr James Williams February 2016 Agenda today 1. Who we are 2. Snapshot and financials 3. Market and long-term growth strategy
More informationIntec. Pharma Unfolding drug delivery solutions. Investor Presentation. Nasdaq: NTEC. June 2017
Intec Pharma Unfolding drug delivery solutions Investor Presentation Nasdaq: NTEC June 2017 Forward Looking Statements This presentation by Intec Pharma Ltd. (referred to as we or our ) contains forward-looking
More informationClinical Research at MSU
Financial Administration Development Program: Clinical Research at MSU Kristen Burt, Office of Regulatory Affairs (ORA) Sharon Schooley, Clinical & Translational Sciences Institute (CTSI) February 24,
More informationApplication of Deep Learning to Drug Discovery
Application of Deep Learning to Drug Discovery Hiroshi Tanaka Tohoku Medical Megabank Orga nization, Tohoku University Current Situation of Drug Discovery Rapid increase of R&D expenditure More than 1B
More informationContent Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA )
Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA ) Area 1.0 Basic Biomedical Sciences (10%) Area 2.0 Pharmaceutical Sciences (33%) Area 3.0 Social/Behavioral/Administrative Sciences (22%)
More informationTISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS
TISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS HLC101B August 2014 Yojana Jeevane Project Analyst ISBN: 1-56965-894-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationGood morning and thank you for joining us for our quarterly update.
Q1 2018 Earnings Conference Call May 7, 2018 11:00 AM ET Introduction and Forward Looking Statements in APPENDIX I Garo Armen Good morning and thank you for joining us for our quarterly update. We have
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationINTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of
More informationCorporate Presentation. Roberto Bellini President and Chief Executive Officer
Corporate Presentation Roberto Bellini President and Chief Executive Officer September 2012 Forward Looking Statement Certain statements contained in this presentation, other than statements of fact that
More informationMRC Technology. A Life Science Specialist Technology Transfer Company. Skaggs School of Pharmacy and Pharmaceutical Sciences, December 2011
MRC Technology A Life Science Specialist Technology Transfer Company Skaggs School of Pharmacy and Pharmaceutical Sciences, December 2011 Dr John Kelly, Associate Director Business Development John.kelly@tech.mrc.ac.uk
More informationNovartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program
Novartis Business Services HR University Relations Clinical Sciences and Innovation Postgraduate Program 2 CLINICAL SCIENCES AND INNOVATION CLINICAL SCIENCES AND INNOVATION 3 The CS&I Postgraduate Program
More informationStem Cells. Part 1: What is a Stem Cell? STO Stem cells are unspecialized. What does this mean?
STO-120 Stem Cells Part 1: What is a Stem Cell? Stem cells differ from other kinds of cells in the body. When a stem cell divides by mitosis, each new cell has the potential to either remain a stem cell
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationEMBRYONIC STEM CELL RESEARCH: ALTERNATIVE METHODS & ALZHEIMER S DISEASE
EMBRYONIC STEM CELL RESEARCH: ALTERNATIVE METHODS & ALZHEIMER S DISEASE BY KHYATI PATEL Word count: Approx 2300 Grade awarded June 2006: PASS WITH DISTINCTION RESEARCH PAPER BASED ON PATHOLOGY LECTURES
More informationBIOL5 (JUN14BIOL501) General Certificate of Education Advanced Level Examination June Unit 5 Control in cells and in organisms
Centre Number Surname Candidate Number For Examiner s Use Other Names Candidate Signature Examiner s Initials Biology General Certificate of Education Advanced Level Examination June 2014 BIOL5 Question
More informationConference call transcript for the March 2017 Quarterly Report
ASX ANNOUNCEMENT Conference call transcript for the March 2017 Quarterly Report Sydney Australia, 31 May 2017: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its transcript
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More informationThe Innovative Medicines Initiative Socio-economic impacts
The Innovative Medicines Initiative Socio-economic impacts Pierre Meulien, IMI Executive Director European Innovation Summit European Parliament 08.12.2015 Closed & open innovation Filing Approval HTA
More informationAnnual General Meeting Roche Holding Ltd 6 March 2012
r Annual General Meeting Roche Holding Ltd 6 March 2012 Address by Franz B. Humer Chairman of the Board of Directors (Check against delivery.) Address by Franz B. Humer Page 2/12 Dear Shareholders, Ladies
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationNew Business Opportunities for Companies Serving Pharma November 2007
New Business Opportunities for Companies Serving Pharma November 2007 In this Issue: Pharma Sales: Lead Activity Report. 1 Lead Sampler.... 1 Sales Article: 7 Top Tips for Increasing Your Business Sales
More informationPassive Immunization Trials to Inform Vaccine Design
Passive Immunization Trials to Inform Vaccine Design Points for Consideration from deliberations held at the August 8, 2014 workshop Contents I. Introduction... 2 II. Types of trials... 2 1. Therapeutic
More informationBiogen Idec Neurology Pipeline. Alfred Sandrock, MD, PhD SVP, Neurology Research & Development
Biogen Idec Neurology Pipeline Alfred Sandrock, MD, PhD SVP, Neurology Research & Development March 25, 2009 Robust Neurology Pipeline Neurology Multiple Sclerosis Discovery Pre-Clinical Phase 1 Phase
More informationTranslational Research
Translational Research Paddy Johnston Chair, MRC Translational Research Overview Group October 2012 Translational Research Strategy and its delivery To accelerate patient benefit and increase economic
More informationTemple of pharma - Speciality Chemicals Magazine
Page 1 of 5 Fine Chemicals Temple of pharma Dr Magid Abou-Gharbia will be bringing the insights from a distinguished career to a key panel discussion at Chemspec USA. We caught up with him at Temple University
More informationTopical sirna for management of androgenic alopecia and oily skin Quark Pharmaceuticals, Inc.
Topical sirna for management of androgenic alopecia and oily skin 1 2017 Quark Pharmaceuticals, Inc. About Quark Founded in 1993; privately held Late stage pharmaceutical company with 2 Phase 3 programs,
More informationManagement Discussion and Analysis for the Second quarter of FY
Management Discussion and Analysis for the Second quarter of FY 2016 17 Revenue Figures Consolidated (Rs. In Millions) Average conversion rate in Q2 FY 2016 17 considered is 66.85 /USD 1.00 Average conversion
More informationIdorsia Company Profile
Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has
More informationBasic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials
Administrative Notice October 27, 2014 To: Prefectural Health Department (Bureau) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Basic
More informationDoctor of Pharmacy Course Descriptions
Doctor of Pharmacy Course Descriptions Required Courses Pharmacy Practicum II (7002) Second practicum with direct instruction by an experienced preceptor to increase the student's awareness of the pharmacist's
More informationTo Our Shareholders: Reaching Patients with PNH and ahus
To Our Shareholders: In 2014, Alexion continued to expand its commercial and clinical operations as we advanced our mission to develop and deliver life-transforming therapies for patients with severe and
More informationAlliance for Regenerative Medicine
Alliance for Regenerative Medicine Michael Werner Executive Director Alliance for Regenerative Medicine ARM s Focus & Role As the leading global advocate for the regenerative medicine and advanced therapies
More informationADDING VALUE TO A PRODUCT S LIFE CYCLE MANAGEMENT: Product Enhancement Through Drug Delivery Systems
ADDING VALUE TO A PRODUCT S LIFE CYCLE MANAGEMENT: Product Enhancement Through Drug Delivery Systems Anand Baichwal, Ph.D. Sr. VP of Research & New Technology Development, and Chief Scientific Officer
More informationREGENXBIO Inc. Ticker: RGNX
REGENXBIO Inc. Ticker: RGNX I know what you are thinking. You are about to read another biotech report with more acronyms than words you know the definitions. I promise you this report is written in layman
More information